Therini Bio
Biotechnology company focused on developing therapeutics for neurodegenerative diseases and age-related conditions. Raised $39 million in Series A funding in May 2025.
Notes
Therini Bio is a biotechnology company focused on developing therapeutics for neurodegenerative diseases and age-related conditions. The company is headquartered in Boston, Massachusetts.
The company is working on novel approaches to treat diseases of aging, with a particular focus on neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease. Therini Bio is backed by Apollo Health Ventures, which specializes in longevity and aging-related biotechnology investments.
In May 2025, Therini Bio raised $39 million in Series A funding to advance its pipeline of neurodegenerative disease therapeutics.
Team
- Leadership team information not publicly disclosed
Additional Research Findings
- Raised $39 million in Series A (May 2025)
- Backed by Apollo Health Ventures
- Neurodegenerative disease focus
- Age-related disease therapeutics
- Boston, Massachusetts headquarters
- Founded in 2022
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Apollo Health Ventures | Dusseldorf, Germany / Boston, USA | biotech-focused | seedseries-a+1 | 15 |